Cargando…

Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk

PURPOSE: Multiplex gene panel testing (MGPT) allows for the simultaneous analysis of germline cancer susceptibility genes. This study describes the diagnostic yield and patient experiences of MGPT in diverse populations. PATIENTS AND METHODS: This multicenter, prospective cohort study enrolled parti...

Descripción completa

Detalles Bibliográficos
Autores principales: Idos, Gregory E., Kurian, Allison W., Ricker, Charité, Sturgeon, Duveen, Culver, Julie O., Kingham, Kerry E., Koff, Rachel, Chun, Nicolette M., Rowe-Teeter, Courtney, Lebensohn, Alexandra P., Levonian, Peter, Lowstuter, Katrina, Partynski, Katlyn, Hong, Christine, Mills, Meredith A., Petrovchich, Iva, Ma, Cindy S., Hartman, Anne-Renee, Allen, Brian, Wenstrup, Richard J., Lancaster, Johnathan M., Brown, Krystal, Kidd, John, Evans, Brent, Mukherjee, Bhramar, McDonnell, Kevin J., Ladabaum, Uri, Ford, James M., Gruber, Stephen B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260917/
https://www.ncbi.nlm.nih.gov/pubmed/34322651
http://dx.doi.org/10.1200/PO.18.00217
_version_ 1783718904463360000
author Idos, Gregory E.
Kurian, Allison W.
Ricker, Charité
Sturgeon, Duveen
Culver, Julie O.
Kingham, Kerry E.
Koff, Rachel
Chun, Nicolette M.
Rowe-Teeter, Courtney
Lebensohn, Alexandra P.
Levonian, Peter
Lowstuter, Katrina
Partynski, Katlyn
Hong, Christine
Mills, Meredith A.
Petrovchich, Iva
Ma, Cindy S.
Hartman, Anne-Renee
Allen, Brian
Wenstrup, Richard J.
Lancaster, Johnathan M.
Brown, Krystal
Kidd, John
Evans, Brent
Mukherjee, Bhramar
McDonnell, Kevin J.
Ladabaum, Uri
Ford, James M.
Gruber, Stephen B.
author_facet Idos, Gregory E.
Kurian, Allison W.
Ricker, Charité
Sturgeon, Duveen
Culver, Julie O.
Kingham, Kerry E.
Koff, Rachel
Chun, Nicolette M.
Rowe-Teeter, Courtney
Lebensohn, Alexandra P.
Levonian, Peter
Lowstuter, Katrina
Partynski, Katlyn
Hong, Christine
Mills, Meredith A.
Petrovchich, Iva
Ma, Cindy S.
Hartman, Anne-Renee
Allen, Brian
Wenstrup, Richard J.
Lancaster, Johnathan M.
Brown, Krystal
Kidd, John
Evans, Brent
Mukherjee, Bhramar
McDonnell, Kevin J.
Ladabaum, Uri
Ford, James M.
Gruber, Stephen B.
author_sort Idos, Gregory E.
collection PubMed
description PURPOSE: Multiplex gene panel testing (MGPT) allows for the simultaneous analysis of germline cancer susceptibility genes. This study describes the diagnostic yield and patient experiences of MGPT in diverse populations. PATIENTS AND METHODS: This multicenter, prospective cohort study enrolled participants from three cancer genetics clinics—University of Southern California Norris Comprehensive Cancer Center, Los Angeles County and University of Southern California Medical Center, and Stanford Cancer Institute—who met testing guidelines or had a 2.5% or greater probability of a pathogenic variant (N = 2,000). All patients underwent 25- or 28-gene MGPT and results were compared with differential genetic diagnoses generated by pretest expert clinical assessment. Post-test surveys on distress, uncertainty, and positive experiences were administered at 3 months (69% response rate) and 1 year (57% response rate). RESULTS: Of 2,000 participants, 81% were female, 41% were Hispanic, 26% were Spanish speaking only, and 30% completed high school or less education. A total of 242 participants (12%) carried one or more pathogenic variant (positive), 689 (34%) carried one or more variant of uncertain significance (VUS), and 1,069 (53%) carried no pathogenic variants or VUS (negative). More than one third of pathogenic variants (34%) were not included in the differential diagnosis. After testing, few patients (4%) had prophylactic surgery, most (92%) never regretted testing, and most (80%) wanted to know all results, even those of uncertain significance. Positive patients were twice as likely as negative/VUS patients (83% v 41%; P < .001) to encourage their relatives to be tested. CONCLUSION: In a racially/ethnically and socioeconomically diverse cohort, MGPT increased diagnostic yield. More than one third of identified pathogenic variants were not clinically anticipated. Patient regret and prophylactic surgery use were low, and patients appropriately encouraged relatives to be tested for clinically relevant results.
format Online
Article
Text
id pubmed-8260917
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-82609172021-07-27 Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk Idos, Gregory E. Kurian, Allison W. Ricker, Charité Sturgeon, Duveen Culver, Julie O. Kingham, Kerry E. Koff, Rachel Chun, Nicolette M. Rowe-Teeter, Courtney Lebensohn, Alexandra P. Levonian, Peter Lowstuter, Katrina Partynski, Katlyn Hong, Christine Mills, Meredith A. Petrovchich, Iva Ma, Cindy S. Hartman, Anne-Renee Allen, Brian Wenstrup, Richard J. Lancaster, Johnathan M. Brown, Krystal Kidd, John Evans, Brent Mukherjee, Bhramar McDonnell, Kevin J. Ladabaum, Uri Ford, James M. Gruber, Stephen B. JCO Precis Oncol Original Report PURPOSE: Multiplex gene panel testing (MGPT) allows for the simultaneous analysis of germline cancer susceptibility genes. This study describes the diagnostic yield and patient experiences of MGPT in diverse populations. PATIENTS AND METHODS: This multicenter, prospective cohort study enrolled participants from three cancer genetics clinics—University of Southern California Norris Comprehensive Cancer Center, Los Angeles County and University of Southern California Medical Center, and Stanford Cancer Institute—who met testing guidelines or had a 2.5% or greater probability of a pathogenic variant (N = 2,000). All patients underwent 25- or 28-gene MGPT and results were compared with differential genetic diagnoses generated by pretest expert clinical assessment. Post-test surveys on distress, uncertainty, and positive experiences were administered at 3 months (69% response rate) and 1 year (57% response rate). RESULTS: Of 2,000 participants, 81% were female, 41% were Hispanic, 26% were Spanish speaking only, and 30% completed high school or less education. A total of 242 participants (12%) carried one or more pathogenic variant (positive), 689 (34%) carried one or more variant of uncertain significance (VUS), and 1,069 (53%) carried no pathogenic variants or VUS (negative). More than one third of pathogenic variants (34%) were not included in the differential diagnosis. After testing, few patients (4%) had prophylactic surgery, most (92%) never regretted testing, and most (80%) wanted to know all results, even those of uncertain significance. Positive patients were twice as likely as negative/VUS patients (83% v 41%; P < .001) to encourage their relatives to be tested. CONCLUSION: In a racially/ethnically and socioeconomically diverse cohort, MGPT increased diagnostic yield. More than one third of identified pathogenic variants were not clinically anticipated. Patient regret and prophylactic surgery use were low, and patients appropriately encouraged relatives to be tested for clinically relevant results. American Society of Clinical Oncology 2019-03-28 /pmc/articles/PMC8260917/ /pubmed/34322651 http://dx.doi.org/10.1200/PO.18.00217 Text en © 2018 by American Society of Clinical Oncology https://creativecommons.org/licenses/by/4.0/Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by/4.0/
spellingShingle Original Report
Idos, Gregory E.
Kurian, Allison W.
Ricker, Charité
Sturgeon, Duveen
Culver, Julie O.
Kingham, Kerry E.
Koff, Rachel
Chun, Nicolette M.
Rowe-Teeter, Courtney
Lebensohn, Alexandra P.
Levonian, Peter
Lowstuter, Katrina
Partynski, Katlyn
Hong, Christine
Mills, Meredith A.
Petrovchich, Iva
Ma, Cindy S.
Hartman, Anne-Renee
Allen, Brian
Wenstrup, Richard J.
Lancaster, Johnathan M.
Brown, Krystal
Kidd, John
Evans, Brent
Mukherjee, Bhramar
McDonnell, Kevin J.
Ladabaum, Uri
Ford, James M.
Gruber, Stephen B.
Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk
title Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk
title_full Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk
title_fullStr Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk
title_full_unstemmed Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk
title_short Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk
title_sort multicenter prospective cohort study of the diagnostic yield and patient experience of multiplex gene panel testing for hereditary cancer risk
topic Original Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260917/
https://www.ncbi.nlm.nih.gov/pubmed/34322651
http://dx.doi.org/10.1200/PO.18.00217
work_keys_str_mv AT idosgregorye multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT kurianallisonw multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT rickercharite multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT sturgeonduveen multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT culverjulieo multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT kinghamkerrye multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT koffrachel multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT chunnicolettem multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT roweteetercourtney multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT lebensohnalexandrap multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT levonianpeter multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT lowstuterkatrina multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT partynskikatlyn multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT hongchristine multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT millsmereditha multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT petrovchichiva multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT macindys multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT hartmanannerenee multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT allenbrian multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT wenstruprichardj multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT lancasterjohnathanm multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT brownkrystal multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT kiddjohn multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT evansbrent multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT mukherjeebhramar multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT mcdonnellkevinj multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT ladabaumuri multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT fordjamesm multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk
AT gruberstephenb multicenterprospectivecohortstudyofthediagnosticyieldandpatientexperienceofmultiplexgenepaneltestingforhereditarycancerrisk